Accelevation

Strategy centers on organic capacity adds and program wins, complemented by M&A (e.g., Instor) that broadened from containment into installation and white‑space services under prior ownership, and a 2025 change of control to Olympus Partners.

While integration created a stronger offering and supported rapid growth, the Up‑C structure, TRA, and a large 40m‑share S‑8 for equity incentives heighten dilution risk. IPO proceeds primarily reduced debt rather than funding outsized organic bets, which is sensible but leaves leverage meaningful.

We do not yet have a track record of disciplined buybacks or clearly accretive, measured M&A as a public company.